On November 13, 2017, a press release formally recognized Ann Anderson Kiessling as a pioneer in HIV and stem cell research.
On November 13, 2017, a formal press release was issued recognizing Ann Anderson Kiessling as a pioneer in HIV and stem cell research. The announcement highlighted her scientific contributions spanning several decades, most notably her discovery of reverse transcriptase activity in normal human cells—a finding that extended understanding of this important enzyme beyond its original identification in retroviruses—as well as her leadership of the Bedford Research Foundation.
This recognition served to consolidate and publicize a career that had, in many respects, operated somewhat outside the mainstream spotlight of major research universities, since much of Kiessling's later work was conducted through her independent nonprofit foundation rather than a traditional academic department. The press release format itself reflects the way many women scientists—particularly those working through smaller or independent institutions rather than as tenured professors at flagship universities—have historically had to rely on more grassroots forms of public recognition rather than named professorships or major prizes.
The recognition specifically credited her with bridging virology and reproductive/stem cell biology, two fields that intersected powerfully in her research on HIV transmission via seminal fluid and in her techniques for safely processing biological specimens from HIV-positive individuals for use in fertility treatment and research.
This 2017 honor helped ensure that Kiessling's foundational scientific contributions, made decades earlier, received public documentation and lasting acknowledgment.